Hantavirus is a group of viruses spread mainly by rodents. It can cause Hantavirus Pulmonary Syndrome (HPS) with severe respiratory symptoms or Hemorrhagic Fever with Renal Syndrome (HFRS) affecting the kidneys.

How is hantavirus transmitted?

Hantavirus is primarily transmitted by inhaling air contaminated with rodent urine, droppings, or saliva. Direct contact with rodents or their nesting materials can also spread the virus. Person-to-person transmission is rare but has been documented with Andes virus.

What are the symptoms of hantavirus?

Early symptoms include fatigue, fever, and muscle aches. After 4-10 days, patients may develop coughing and shortness of breath as the lungs fill with fluid. HFRS symptoms include intense headaches, back pain, and kidney problems.

Where are hantavirus outbreaks most common?

Hantavirus outbreaks occur worldwide. HPS is most common in North and South America, while HFRS is prevalent in Europe and Asia. Argentina, Chile, and Patagonia region have seen notable Andes virus cases.

Medical Information - Consult Healthcare Providers

Hantavirus Treatment

There is no specific cure or vaccine for hantavirus. Treatment focuses on intensive supportive care to manage symptoms and prevent complications.

Early Treatment is Critical

Patients who receive intensive care within 48-72 hours of respiratory symptoms have significantly better outcomes. If you suspect hantavirus infection, seek emergency medical care immediately. Do not wait for symptoms to worsen.

Current Medical Reality

×No antiviral drugs are approved specifically for hantavirus
×No vaccine is available for prevention (though some are in development)
×Antibiotics don't work - hantavirus is a virus, not bacteria
✓Supportive care in intensive care units saves lives

Treatment for HPS (Hantavirus Pulmonary Syndrome)

Intensive Care Unit (ICU) Support

Patients with HPS typically require ICU admission for close monitoring and aggressive supportive care. The goal is to support organ function while the immune system fights the virus.

Oxygen Therapy

Supplemental oxygen via mask or nasal cannula for mild cases

Mechanical Ventilation

Breathing machine for severe respiratory distress

ECMO

Extracorporeal membrane oxygenation for critical cases - acts as external heart/lung

IV Fluids

Careful fluid management - too much can worsen lung edema

Vasopressors

Medications to maintain blood pressure if shock develops

Continuous Monitoring

24/7 vital sign monitoring and blood gas analysis

ECMO: The Life-Saving Option

Extracorporeal Membrane Oxygenation (ECMO) has dramatically improved survival rates for severe HPS cases. This machine:

•Removes blood from the body and oxygenates it externally
•Returns oxygenated blood while lungs recover
•Can keep patients alive through the critical phase
•Only available at specialized medical centers

Treatment for HFRS (Hemorrhagic Fever with Renal Syndrome)

HFRS treatment focuses on maintaining kidney function and managing hemorrhagic complications:

Dialysis

Temporary kidney replacement therapy if kidneys fail

Fluid Balance

Careful IV fluid management during different phases

Blood Pressure Control

Medications for hypotension during shock phase

Blood Transfusions

May be needed if significant bleeding occurs

Pain Management

Medications for severe back and abdominal pain

Ribavirin (Experimental)

Antiviral may reduce mortality if given early (used in some countries)

Research & Experimental Treatments

Ribavirin

An antiviral drug used for some HFRS cases in Asia and Europe. Studies show potential benefit when given within first 4 days of illness. Not FDA-approved for hantavirus and less effective for HPS.

Convalescent Plasma

Blood plasma from recovered patients containing antibodies. Has shown promise in limited studies for Andes virus infection. Research ongoing.

Vaccines in Development

Several vaccine candidates are in clinical trials, including DNA vaccines and inactivated virus vaccines. No vaccine is currently approved for human use in Western countries (China and South Korea have licensed vaccines for HFRS).

Survival & Recovery

HPS Mortality

30-40%

Overall mortality rate

• Early ICU care significantly improves odds
• ECMO can save critical cases
• Most deaths occur within 48 hours of respiratory failure

HFRS Mortality

1-15%

Varies by virus strain

• Puumala (Europe): <1% mortality
• Hantaan (Asia): 5-15% mortality
• Seoul (worldwide): 1-2% mortality

Recovery Expectations

Patients who survive the acute phase generally make a full recovery, though it can take weeks to months:

•Fatigue may persist for several weeks to months
•Lung function typically returns to normal within 1-2 months
•Kidney function (HFRS) usually recovers fully, though some patients have lasting impairment
•Immunity - survivors develop antibodies and are unlikely to be reinfected with the same strain

Follow-up care with pulmonology or nephrology specialists may be recommended for severe cases.